

Stahl's Illustrated

Index

- 12-step fellowships, 141
- aberrant behavior, 2
- abstinence, 4, 6–7: acamprosate, 52; disulfiram, 56; familial support, 140; mutual support groups, 141; naltrexone, 54, 73; and reduced-risk drinking, 48–9; smoking, 85, 94; from stimulant use, 109; topiramate, 57
- abuse, defined, 2
- acamprosate, alcohol abstinence, 52–3
- acetylcholine (ACh), 16, 78, 151
- acute withdrawal, mechanism of, 30–1
- addiction, 1–2: neurobiology of, 24–5; patterns of, 6–7; risk factors for, 5
- addiction cycle, 4, 28–9
- aggression, impulsive, 149–51
- alcohol, 35: consumption and risk of AUD, 41; mechanism of action in the VTA, 36–7; mechanism of dopamine increase, 14; monitoring and follow-up, 60; pattern of addiction, 6–7; pharmacological treatments, 50–7; psychosocial treatment, 51; recommended drinking limits, 40; reduced-risk drinking, 48–9; screening methods, 42–3; standard drink, 38–9; treatment strategies, 44–7; withdrawal syndrome, treatment of, 58–9
- alcohol withdrawal syndrome (AWS), treating, 58–9
- alpha 4 beta 2 nicotinic receptors, 78–81
- amotivational syndrome, long-term marijuana use, 116
- AMPA/NMDA receptor ratio, 26–7
- amphetamine, 99–103
- amygdala: CRF activation during acute withdrawal, 30–1; and flashbacks, 127; impulsive aggression, 150–1; role in reward system, 18–19, 23; stress circuit, 28–9
- anterior cingulate cortex (ACC), 25, 151
- anticonvulsants, 57, 107, 151
- antidepressants, 9, 50, 65, 75, 107
- atypical antipsychotics, aggression, 151
- AUDIT (Alcohol Use Disorders Identification Test), 42–3
- aversion therapy, 136–7
- barbiturates, 123
- “bath salts,” 131
- behavioral addictions see impulse control disorders (ICDs)
- behavioral therapies, 136–7
- benzodiazepines (BZs): for alcohol withdrawal, 50, 59; alternative to barbiturates, 123; for opioid withdrawal, 75

- brain stress system, 28–9
- brief intervention for smoking cessation, 83
- buprenorphine, 70–1: DEA DATA 2000
 waiver to prescribe, 72; opioid
 withdrawal treatment, 65, 67, 74–5
- bupropion, smoking cessation, 85, 94–5
- cannabinoids (CBs), 16–17: actions on
 reward circuits, 114; mechanism of
 dopamine increase, 14; retrograde
 neurotransmitters, 115
- clonidine/naltrexone, 74–5
- clonidine, opioid withdrawal, 74–5
- club drugs, 128–9
- cocaethylene, 106
- cocaine, 99–100: effects and treatment, 105;
 and ethanol interaction, cocaethylene,
 106; experimental treatments, 110–11;
 pharmacological treatment, 107;
 progression of abuse, 104; route of
 administration, 103; vs.
 methamphetamine, 101–2; withdrawal
 symptoms, 109
- cocaine esterase (CocE), 111
- cognitive behavioral therapy (CBT), 135–6
- community reinforcement, 136–7
- comorbid psychiatric illness and substance use,
 treatment issues, 8–9
- compulsion/compulsivity, 4, 6: categorization
 of disorders of, 146; drug addiction as
 disorder of, 4, 144; neurobiology of,
 24–5; obsessive compulsive disorder,
 143, 146, 155; stress circuit
 implicated in, 28–9
- conditioning, 23, 56, 104, 127, 151
- contingency management, 136–7
- corticotropin releasing factor (CRF), 28–31,
 33
- craving, 4, 6, 7, 23–5, 144: bupropion
 alleviating, 94; cue exposure therapy,
 137; methadone suppressing, 69;
 nicotine patches controlling, 90
- cue exposure, 136–7
- delta-9-tetrahydrocannabinol (THC), 114, 119
- delta opioid receptors, 63
- dependence, defined, 2
- “designer drugs,” 125
- diagnostic criteria *see* DSM-V proposed criteria
- dimethyltryptamine (DMT), 125
- disorders of impulsivity and compulsivity, 143:
 gambling disorder, 147; hair pulling,
 skin picking and OCD, 155;
 hypersexual disorder, 152; impulsive
 aggression and IED, 149; proposed
 DSM-5 categorization of, 146;
 pyromania and kleptomania, 148;
 similarities between SUDs and ICDs,
 144–5
- disulfiram, alcohol abstinence, 56
- dopamine (DA) and reward circuit, 12–18:
 actions of alcohol, 36–7, 54; actions of
 nicotine, 78–81, 94; actions of
 opioids, 62; and compulsive
 use/addiction, 25; conditioning
 mechanism, 23; and stimulant abuse,
 100–4; tolerance and acute
 withdrawal, 30–1
- dopamine transporter (DAT), 14, 101–2
- dorsal striatum, 13, 23–5
- dorsolateral prefrontal cortex (DLPFC), 13, 19,
 21, 25
- drinking behavior and risk of AUD, 41
- drinking limits, 40
- dronabinol, marijuana withdrawal, 119
- drug administration route, 82, 103
- DSM criteria for SUDs, similarities to
 ICDs, 145
- DSM-V proposed criteria: hair pulling and skin
 picking, 155; hypersexual disorder,
 152; for ICDs, 146, 155; for SUDs, 3,
 146
- dynorphin (Dyn), 30–2, 63
- dysphoria, 6, 7, 32, 63–4, 144

- "ecstasy," 125
 endocannabinoids, 115
 endogenous opioids, 49, 54, 62–3
 enkephalin, 28, 36–7, 62–3
 epigenetic mechanisms, 5, 33
 exogenous opioids, 63
- family therapy, 140
 flashbacks, hallucinogen abuse, 127
 follow-up: alcohol use disorder, 60; opioid withdrawal, 67; smoking cessation, 84
 food addiction, 154
 "foxy" (5-methoxydiisopropyltryptamine), 125
 freon, "huffing" of, 131
- GABA (gamma aminobutyric acid), 14, 16–19, 22–3: acamprosate effects, 52; alcohol effects, 36–7; and anxiety/panic attacks in MWS, 32; nicotine effects, 78–9; role in tolerance and acute withdrawal, 30–1; sedative hypnotics, 122–3; topiramate effects, 57
- gambling disorder, 147
 genetic contributions to addiction, 5
 glutamate (glu), 16, 30: acamprosate effects on, 52; action of club drugs, 128; and acute withdrawal, 31; and alcohol action in the VTA, 36–7; and development of addiction, 26–7; and nicotine action in the VTA, 78–9; topiramate's effects on, 57
 goal-directed behavior, output of reward system, 22
 gum, nicotine replacement therapy, 88–9
- hair pulling disorder, 146, 155
 hallucinogens, 124–5: long-term effects, 127; mechanism of action, 126–7
 huffing, 131
 hypersexual disorder, 152
- impulse control disorders (ICDs), 143: criteria for SUBs applicable to, 145; food addiction, 154; intermittent explosive disorder (IED), 149; Internet addiction, 153; pathological gambling, 147; proposed DSM-5 categorization of, 146; pyromania and kleptomania, 148; versus SUDs, 144
 impulsion/impulsivity: brain circuits implicated in, 28–9; impulsive aggression, 149–51; progression to compulsivity, 4
 impulsive aggression, 149–51
 intermittent explosive disorder (IED), 149
 Internet addiction, 153
 interpersonal therapy (IPT), 139
 intoxication, 4, 6, 7: effects of phencyclidine (PCP), 129; symptoms of hallucinogenic, 125; symptoms of marijuana, 116; symptoms of opioid, 64; treatment of stimulant, 105
 irritability, 7, 32, 75, 105, 119, 151
- kappa opioid receptors, 63
 ketamine, 128–9
 kleptomania, 148
- long-term potentiation (LTP), 27
 lozenges, nicotine replacement therapy, 88, 93
 LSD (D-lysergic acid diethylamide), 125
- marijuana, 7, 113: actions on reward circuits, 114; effects of, 116; pattern of addiction, 6–7; pharmacological treatment, 117; psychosocial treatment, 118; and retrograde neurotransmission, 115; withdrawal symptoms, 119
- MDMA (3,4-methylenedioxymethamphetamine), 125, 127
- mephedrone in "bath salts," 131
 mesolimbic dopamine pathway, 12–13

- metabotropic glutamate receptor (mGluR), 36–7
- methadone, 65, 67–9, 74–5
- methamphetamine, 99–105, 109
- methylenedioxypyrovalerone (MDPV), 131
- methylone in “bath salts”, 131
- methylphenidate, 99–103
- misuse, defined, 2
- monitoring of AUD patients, 60
- motivational enhancement therapy (MET), 138
- motivational interviewing, 138
- motivational withdrawal syndrome (MWS), 32
- mu opioid receptor (MOR), 14, 16: actions of alcohol, 36–7, 54; buprenorphine, 70; methadone, 69; naloxone, 71; naltrexone, 54, 73; reinforcement role, 63
- multiple substance use, 9, 27
- N*-methyl-D-aspartate (NMDA), 26–7, 36–7, 52, 129
- naloxone, 71, 75
- naltrexone: for alcohol use disorder, 54–5; kleptomania treatment, 148; for opioid use disorder, 67, 73; opioid withdrawal treatment, 74–5
- nasal inhalers, 88, 92
- nasal sprays, 88, 91
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), 40–1, 43
- neurobiology of reward and drug addiction, 11: acute withdrawal, 30–1; addiction cycle and brain stress system, 28–9; compulsive use/addiction, 24–5; conditioning to reward cues, 23; dopamine and reward, 12–15; goal-directed behavior, turning reward into, 22; loss of control over drug use, 26–7; motivational withdrawal syndrome (MWS), 32; neurotransmitter regulation of mesolimbic reward, 16; reactive reward system, 18; reflective reward system, 19; relapse, 33; substrates for reinforcing effects of drugs, 17; temptation vs. willpower, 20–1; tolerance development, 30–1
- neuropeptide Y (NPY), 30–2
- neurotransmitters, 16, 17, 30–1: endocannabinoids as retrograde, 115; endogenous opioid, 63; involved in symptoms of MWS, 32
- nicotine, 77: actions in the VTA, 78–9; alpha 4 beta 2 nicotine receptors, 80–1; brief intervention for smoking cessation, 83; dopamine increase, mechanism of, 14; effects of, function of delivery mode, 82; management strategy, 84; pattern of addiction, 6–7; pharmacological treatment, 85, 94–7; psychosocial treatment, 86–7; replacement therapy, 88–93
- nicotine replacement therapy, 82, 85, 88: nicotine gum, 89; nicotine inhalers, 92; nicotine lozenges, 93; nicotine nasal spray, 91; nicotine patch, 90
- nicotine vaccine, 85
- nicotinic receptors, 14, 78–81
- NMDA (*N*-methyl-d-aspartate) receptors, 26–7, 36, 37, 52, 129
- norepinephrine (NE), 28, 30–3, 94, 101, 125
- nucleus accumbens (NAc), reward system, 12–14, 16–22: action of opioids on, 62–3; actions of hallucinogens, 124–5; actions of marijuana on, 114; actions of nicotine on, 79; actions of stimulants on, 100; bupropion's effects, 94; implicated in relapse, 33
- obesity, 154
- obsessive compulsive disorder (OCD), 143, 146, 155

- opioid receptors, 16, 37, 54, 63, 69, 70, 73, 147
- opioids, 61: actions on reward circuits, 62; endogenous opioid neurotransmitters, 63; mechanism of dopamine increase, 14; pattern of addiction, 6–7; pharmacological treatment, 65, 68–73; psychosocial treatment for OUD, 66; screening for misuse of, 64; treatment settings, 67; withdrawal treatment, 74–5
- orbitofrontal cortex (OFC), 19, 21, 25, 151
- panic, 32, 116, 125
- pharmacological treatment: for alcohol use disorder, 50, 52–7; for alcohol withdrawal syndrome (AWS), 58–9; for marijuana use disorder, 117; for opioid use disorder, 65; for stimulant use disorder, 107
- phencyclidine (PCP), 128–9
- precursor proteins, 63
- prefrontal cortex (PFC), 13, 19, 21: and compulsive use/addiction, 24–5; and goal-directed behavior, 22; hypoactivity in impulsive aggression, 151; hypoactivity in obese patients, 154; and loss of control over drug use, 26–7
- pregnancy: and nicotine replacement therapies, 88; and reduced-risk drinking, 49
- prescription opioids, overdose from, 61
- pro-opiomelanocortin (POMC), 63
- pseudo-addiction, 2
- psychiatric illness and comorbid substance use, treatment issues, 8–9
- psychosocial treatment, 133–4: 12-step facilitation/fellowships, 141; for alcohol use disorder, 51; behavioral therapy, 136–7; cognitive behavioral therapy (CBT), 135–6; family therapy, 140; interpersonal therapy (IPT), 139; for marijuana use disorder, 118; motivational enhancement therapy (MET), 138; for nicotine dependence, 86–7; for opioid use disorder, 66; for stimulant use disorder, 108
- pyromania, 148
- reactive reward system, 18–19, 21, 27, 154
- recommended drinking limits, 40
- reduced-risk drinking, 48–9
- reflective reward system, 19, 21–2, 25, 27
- reinforcement, 4, 12, 16, 30: and alpha 4 beta 2 nicotine receptors, 80–1; and dopamine increase, 15, 103; and glutamatergic dysfunction, 27; mu receptors in the VTA, 63; substrates, 17
- relapse, 33
- reward circuits: activated in addiction, 28–9; dopamine mesolimbic pathway, 12–13; marijuana and THC actions on, 114; opioid actions on, 62; stimulant actions on, 100
- risk factors: for addiction, 5; for relapse, 33
- screening methods: alcohol use disorder, 42–3; opioid misuse, 64
- sedative hypnotics, 122–3
- serotonin (5HT), 16: and dysphoria, 32; and hallucinogens, 124–7; regulation of aggression, 151
- SERT (serotonin transporter), 126–7
- skin picking disorder, 155
- smoking cessation: brief intervention, 83; management strategy, 84; nicotine replacement therapy, 88–93; pharmacological treatment, 85, 94–7; psychosocial treatment, 86–7
- SSRIs (selective serotonin reuptake inhibitors), 50, 151–2
- standard drinks, 38–9

- stimulants, 99: abuse potential, 103; actions on reward circuits, 100; cocaethylene, 106; cocaine vs. methamphetamine, 101–2; effects and treatments, 105; experimental treatments, 110–11; mechanism of dopamine increase, 14; pattern of addiction, 6–7; pharmacological treatments, 107; progression of abuse, 104; psychosocial treatment, 108; synthetic, “bath salts,” 131; withdrawal from, 109
- stress: brain circuit implicated in addiction, 28, 29; during acute withdrawal, 31; neurotransmitters linked to, 32; relapse trigger, 27, 33; risk factor for addiction, 5, 33
- striatum, 13, 15, 22–5
- substance use disorders (SUDs): and comorbid psychiatric illness, 8–9; proposed DSM-V criteria, 3, 146; similarities with ICDs, 144–5
- support groups, 141
- synthetic drugs, 125, 131
- telephone quit lines, smoking cessation, 87
- temptation vs. willpower, 20–1
- thalamus, 13, 22, 25
- THC (delta-9-tetrahydrocannabinol), 114, 119
- tolerance, 2, 6–7; development of, 30–1; hallucinogens, 127
- topiramate, 50, 57, 59
- trends for getting high, 130–1
- trichotillomania (hair pulling disorder), 146, 155
- tricyclic antidepressants (TCAs), 9, 50, 107
- Twelve-Step Facilitation (TSF), 141
- twelve-step fellowships, 141
- vaccines: cocaine dependence, 110, 111; nicotine dependence, 85
- varenicline, smoking cessation, 85, 96–7
- ventral tegmental area (VTA), 12, 14, 16, 17, 28: actions of alcohol in, 36–7; actions of nicotine in, 78–9; and actions of opioids, 62–3; and drug-induced craving, 24–5; and loss of control over drug use, 27; reactive reward system, 18; and temptation, 20–1
- ventromedial prefrontal cortex (VMPFC), 13, 19
- vesicular monoamine transporter (VMAT), 102
- voltage-sensitive calcium channels (VSCC), 36, 37
- willpower vs. temptation, 20–1
- withdrawal, 4: acute, mechanism of, 30–1; alcohol withdrawal syndrome, 58–9; marijuana, 119; motivational withdrawal syndrome, 32; opioids, symptoms of, 64; opioids, treatment of, 67, 74–5; stimulants, 109